Filing Flows › Traws Pharma (TRAW) › Q2 2025
Traws Pharma (TRAW) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Traws Pharma (TRAW) reported revenue of $2.7M for the second quarter 2025 (Q2 2025), up 48-fold from a year earlier and up 48-fold from the quarter before. Operating margin was -45.7%, net loss $915K (33.5% of revenue).
Traws Pharma, Q2 2025: revenue $2.7M (48× year over year), operating margin -45.7%, net loss $915K, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.7M | 48× | 48× |
| Operating profit | −$1.2M | — | — |
| Net earnings | −$915K | -104% | — |
| Operating cash flow | −$6.0M | — | — |
What changed
Revenue was $2.7M in Q2 2025, up 4695% year over year and up 4695% from the previous quarter.
Operating costs exceeded revenue by $1.2M, an operating margin of -45.7%. Total costs fell 97% while revenue rose 4695%. The quarter ended with a net loss of $915K, after a profit of $21.5M the previous quarter. Non-operating items added $334K, -37% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$6.0M. Non-cash charges added back $1K of depreciation and amortization and $105K of share-based compensation. Working capital and other items used $5.2M.
Questions
What was Traws Pharma's revenue in the second quarter 2025?
Traws Pharma (TRAW) reported revenue of $2.7M for the second quarter 2025 (Q2 2025), up 48-fold from a year earlier and up 48-fold from the quarter before.
Was Traws Pharma profitable in the second quarter 2025?
Operating loss was $1.2M (-45.7% of revenue) and net loss $915K.
Source: Traws Pharma 10-Q on SEC EDGAR.